A validated cellular biobank for β-thalassemia

Area of Science:

• Biomedical research
• Cellular biobanking
• Hematology

Background:

• Cellular biobanking is crucial for collaborative research networks.
• It is particularly important for beta-thalassemia studies where patient recruitment and sample collection are challenging.
• This study focuses on creating a specialized biobank for beta-thalassemia research.

Purpose of the Study:

• To establish and validate a biobank of expanded erythroid precursor cells from beta-thalassemia patients.
• To ensure the reliability and reproducibility of biobanked samples for research.

Main Methods:

• Obtained and expanded erythroid precursor cells from 72 patients, primarily with beta-thalassemia.
• Cryopreserved cells and validated their phenotype through multiple sample collections, freezing, and thawing cycles.
• Assessed gene expression (RT-qPCR) and hemoglobin production (HPLC).
• Confirmed reproducibility by shipping cells to different labs for standardized analysis.

Main Results:

• Successfully produced and validated the Thal-Biobank with expanded erythroid precursor cells.
• Demonstrated phenotype maintenance across independent collections, cryopreservation, and thawing.
• Confirmed inter-laboratory reproducibility using standardized protocols.
• Stratified biobanked cells based on fetal hemoglobin levels for further experiments.

Conclusions:

• The Thal-Biobank provides a reliable resource for beta-thalassemia research.
• Biobanked cells allow for patient stratification based on fetal hemoglobin production.
• This resource facilitates reproducible assessment of fetal hemoglobin inducers (e.g., hydroxyurea) and gene therapy efficacy.